XML 201 R160.htm IDEA: XBRL DOCUMENT
v3.20.2

Commitments and Contingencies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) |  |  |  |  | 1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 10 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 13, 2019 USD ($) | Jul. 02, 2019 USD ($) | Apr. 18, 2019 USD ($) ft² | Jul. 31, 2018 USD ($) | Sep. 30, 2018 | Dec. 31, 2018 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 | Jun. 30, 2020 | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Nov. 05, 2018 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Aug. 13, 2020 USD ($) | Jan. 02, 2019 USD ($)
Concentration risk percentage |  |  |  |  |  |  | 100.00% | 100.00% |  | 100.00% | 100.00% |  | 100.00% | 100.00% |  |
Debt instrument principal amount |  |  |  |  |  |  | $ 3,350,100 |  |  | $ 3,350,100 |  |  |  |  |  |
Lease description |  |  |  |  |  |  |  |  |  | The Company has operating leases for its warehouse facility and for equipment under agreements that expire at various dates through 2023. |  |  | The Company has entered into operating leases for office and production facilities and equipment under agreements that expire at various dates through 2026. |  |  |
Operating lease liabilities |  |  |  |  |  | $ 3,458,000 | 5,000 |  |  | $ 5,000 |  |  | $ 3,300,000 | $ 3,458,000 |  | $ 3,458,000
Brooklyn Immunotherapeutics, LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease expiration term |  | Dec. 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rent expense |  | $ 485,061 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease description |  | In connection with the Business Combination, BITX also assumed IRX's lease for laboratory space in Brooklyn, New York (the "Laboratory Lease"), with annual rent expense for the first year of $314,577 beginning on the date of the Business Combination. Effective on July 1, 2019, the Laboratory Lease was amended to increase the space rented under the Laboratory Lease. Annual rent expense (including the Company's pro rata share of operating expenses) for 12 months beginning July 1, 2019 increased to $485,061 pursuant to the amended Laboratory Lease, and the rent increases 3% on January 1 of each lease year. The Laboratory Lease expires on December 31, 2025. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sublease payments |  |  |  |  |  |  |  |  |  | 58,957 | $ 6,535 |  |  |  |  |
Operating lease liabilities |  |  |  |  |  |  | $ 100,700 |  |  | $ 100,700 |  |  | 103,056 |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rent expense |  |  |  |  |  | $ 77,170 |  |  |  |  |  |  | 544,214 |  |  |
Sublease payments |  |  |  |  |  |  |  |  |  |  |  |  | 32,676 |  |  |
Operating lease liabilities |  |  |  |  |  |  |  |  |  |  |  |  | $ 103,350 |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Predecessor [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rent expense |  |  |  |  |  |  |  |  |  |  |  | $ 480,577 |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Office Lease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease expiration term |  |  |  |  |  |  |  |  |  |  |  |  | Nov. 30, 2026 |  |  |
Rent expense |  |  |  |  |  |  |  |  |  |  |  |  | $ 93,275 |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Laboratory Lease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rent expense |  |  |  |  |  |  |  |  |  |  |  |  | $ 314,577 |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Predecessor Royalty Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  |  |  |  |  |  |  |  | 7.00% |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Collaborator Royalty Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  |  |  |  |  |  |  |  |  | 6.00% |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Investor Royalty Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  | 4.00% |  |  |  | 4.00% |  |  |  |  |  |  |
Royalty agreement expiration date, description |  |  |  |  | The Investor Royalty Agreement expires in September 2028. |  |  |  | The Investor Royalty Agreement expires in September 2028. |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | CEO Separation Agreement [Member] | Chief Executive Officer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Severance pay | $ 225,000 |  |  | $ 275,000 |  |  |  |  |  |  |  |  |  |  |  |
Debt instrument principal amount |  |  |  | $ 31,731 |  |  |  |  |  |  |  |  |  |  |  |
Unused vacation time | 37,518 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Health and dental insurance plan | $ 14,032 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | IRX Therapeutics, Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination percentage |  |  |  |  |  |  |  |  |  |  |  |  | 25.00% |  |  |
Legal settlements |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 150,000 |
Brooklyn Immunotherapeutics, LLC [Member] | Nezu Asia Capital Management, LLC [Member] | Sublease Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease expiration term |  |  | Oct. 31, 2026 |  |  |  |  |  |  |  |  |  |  |  |  |
Area of land | ft² |  |  | 999 |  |  |  |  |  |  |  |  |  |  |  |  |
Lease term |  |  | 8 years |  |  |  |  |  |  |  |  |  |  |  |  |
Sublease payments |  |  | $ 78,422 |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in rent expense |  |  | 2.25% |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Health and dental insurance plan. + References No definition available. + Details
Name: | NTN_HealthAndDentalInsurancePlan
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Increase in rent expense. + References No definition available. + Details
Name: | NTN_IncreaseInRentExpense
Namespace Prefix: | NTN_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalty agreement expiration date, description. + References No definition available. + Details
Name: | NTN_RoyaltyAgreementExpirationDateDescription
Namespace Prefix: | NTN_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Severance pay. + References No definition available. + Details
Name: | NTN_SeverancePay
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Unused vacation time. + References No definition available. + Details
Name: | NTN_UnusedVacationTime
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Area of land held. + References No definition available. + Details
Name: | us-gaap_AreaOfLand
Namespace Prefix: | us-gaap_
Data Type: | num:areaItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Date which lease or group of leases is set to expire, in CCYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_LeaseExpirationDate1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980 + Details
Name: | us-gaap_LesseeFinanceLeaseTermOfContract1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of lessee's operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980 + Details
Name: | us-gaap_LesseeOperatingLeaseDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Present value of lessee's discounted obligation for lease payments from operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details
Name: | us-gaap_OperatingLeaseLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash payments to lessor's for use of assets under operating leases. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of sublease income excluding finance and operating lease expense. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 + Details
Name: | us-gaap_SubleaseIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=NTN_SuccessorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=NTN_PredecessorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseContractualTermAxis=NTN_OfficeLeaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseContractualTermAxis=NTN_LaboratoryLeaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_PredecessorRoyaltyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_CollaboratorRoyaltyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_InvestorRoyaltyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_CeoSeparationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=NTN_IRXTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=NTN_NezuAsiaCapitalManagementLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_SubleaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |